Holen Sie sich die Stockscreener-App
32.67
1.69%
-0.56
Schlusskurs vom Vortag:
$33.23
Offen:
$33.24
24-Stunden-Volumen:
728.58K
Relative Volume:
1.26
Marktkapitalisierung:
$1.83B
Einnahmen:
$651.97M
Nettoeinkommen (Verlust:
$59.71M
KGV:
30.54
EPS:
1.0696
Netto-Cashflow:
$172.03M
1W Leistung:
-2.51%
1M Leistung:
+1.21%
6M Leistung:
-14.41%
1J Leistung:
+8.90%
1-Tages-Spanne:
$32.52
$33.72
1-Wochen-Bereich:
$32.20
$34.40
52-Wochen-Spanne:
$27.05
$40.28
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
Firmenname
Supernus Pharmaceuticals Inc
Sektor
Telefon
301-838-2500
Adresse
9715 KEY WEST AVENUE, ROCKVILLE, MD
Vergleichen Sie SUPN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SUPN
Supernus Pharmaceuticals Inc
|
32.67 | 1.88B | 651.97M | 59.71M | 172.03M | 1.0696 |
|
ZTS
Zoetis Inc
|
151.19 | 68.05B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.55 | 46.58B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.65 | 43.71B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.29 | 18.40B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
297.89 | 13.23B | 2.99B | 1.21B | 1.13B | 25.06 |
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-19 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-09-11 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-01-03 | Fortgesetzt | Jefferies | Buy |
| 2021-12-01 | Fortgesetzt | Jefferies | Buy |
| 2021-04-13 | Hochstufung | Jefferies | Hold → Buy |
| 2020-06-16 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2020-06-15 | Fortgesetzt | Jefferies | Hold |
| 2019-11-08 | Herabstufung | Berenberg | Buy → Hold |
| 2019-11-07 | Herabstufung | Stifel | Buy → Hold |
| 2019-11-06 | Herabstufung | Jefferies | Buy → Hold |
| 2018-11-12 | Bestätigt | B. Riley FBR | Buy |
| 2018-01-18 | Bestätigt | B. Riley FBR, Inc. | Buy |
| 2017-12-28 | Bestätigt | B. Riley FBR, Inc. | Buy |
| 2017-12-04 | Hochstufung | Janney | Neutral → Buy |
| 2017-11-08 | Hochstufung | Stifel | Hold → Buy |
| 2017-10-19 | Eingeleitet | FBR & Co. | Buy |
| 2017-09-19 | Herabstufung | Stifel | Buy → Hold |
| 2017-07-17 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2017-07-14 | Eingeleitet | Janney | Neutral |
| 2017-06-01 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-07-18 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2016-07-18 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2016-02-08 | Hochstufung | Jefferies | Hold → Buy |
| 2015-11-05 | Bestätigt | Northland Capital | Outperform |
| 2015-10-28 | Eingeleitet | Northland Capital | Outperform |
Alle ansehen
Supernus Pharmaceuticals Inc Aktie (SUPN) Neueste Nachrichten
What drives Supernus Pharmaceuticals Inc. stock priceFastest return on investment - Autocar Professional
Supernus Pharmaceuticals Inc. Stock Analysis and ForecastOverwhelming financial success - Autocar Professional
Supernus Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 5 - Quiver Quantitative
Supernus Pharmaceuticals to Announce Second Quarter 2025 - GlobeNewswire
Supernus Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 5, 2025 - Yahoo.co
What analysts say about Supernus Pharmaceuticals Inc. stockTremendous portfolio expansion - jammulinksnews.com
Is Supernus Pharmaceuticals Inc. a good long term investmentExplosive trading opportunities - jammulinksnews.com
Supernus Pharmaceuticals Faces 3.2% Share Decline: Sector Challenges ImpactNews and Statistics - IndexBox
(SUPN) Investment Report - news.stocktradersdaily.com
Why Supernus Pharmaceuticals (SUPN) Shares Are Falling Today - Yahoo Finance
Is Supernus Pharmaceuticals Inc. stock a growth or value playQuick Profit Idea Stream - Newser
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Holdings Lowered by Teacher Retirement System of Texas - Defense World
Why Supernus Pharmaceuticals Inc. stock attracts strong analyst attentionTop Rated Trade Entries - Newser
How Supernus Pharmaceuticals Inc. stock performs during market volatilityStrong Buy Recommendations - Newser
What makes Supernus Pharmaceuticals Inc. stock price move sharplyFree Stock Market Expert Consultation - Newser
Principal Financial Group Inc. Boosts Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by Amalgamated Bank - Defense World
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by Allspring Global Investments Holdings LLC - Defense World
When the Price of (SUPN) Talks, People Listen - news.stocktradersdaily.com
Supernus Pharmaceuticals to Acquire Sage Therapeutics in Transaction Valued Up to $795 Million - Global Legal Chronicle
Busy Philipps, Jay Glazer highlight ADHD experiences in Supernus’ campaigns - Medical Marketing and Media
Sage Therapeutics cuts over 300 jobs after securing buyer - The Business Journals
Supernus Pharmaceuticals (NASDAQ:SUPN) shareholders have earned a 6.8% CAGR over the last five years - Yahoo Finance
Supernus to acquire Sage Therapeutics stock for $8.50 per share By Investing.com - Investing.com UK
Supernus to acquire depression drugmaker Sage - MSN
Apomorphine Delivery Device Market Set to Witness Significant - openPR.com
Supernus Pharmaceuticals Gets Retail Excited Over $795M Acquisition Plan For Sage Therapeutics - MSN
Supernus Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks
SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal - Yahoo Finance
These Analysts Revise Their Forecasts On Sage Therapeutics Following Acquisition News - Benzinga
Supernus buys Sage Therapeutics for $561 million as Cantor holds rating - Investing.com Canada
Morning Movers: Sage Therapeutics surges after deal to be acquired by Supernus - Yahoo Finance
Are Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market? - simplywall.st
SAGE to Be Acquired by Supernus Pharmaceuticals | SAGE Stock New - GuruFocus
Trading (SUPN) With Integrated Risk Controls - news.stocktradersdaily.com
Supernus Pharma to acquire Sage Therapeutics in up to $795 million deal - whbl.com
Supernus Pharmaceuticals picks up embattled Sage Therapeutics - Mugglehead Magazine
Supernus Secures Sage With CVR-Supported Deal - insights.citeline.com
Supernus to Acquire Sage Therapeutics in $795M Deal - USA Herald
Saul Ewing-Led Supernus Inks Up To $795M Brain Health Deal - Law360
Deals of the day-Mergers and acquisitions - marketscreener.com
Supernus to acquire Sage Therapeutics for up to $795 million By Investing.com - Investing.com South Africa
Supernus enters depression drug market with up to $795 million Sage deal | Business Information & News | FE - Westlaw Today
Supernus To Acquire Sage: A Smart Move, Despite Both Pharmas' MDD Woes (NASDAQ:SUPN) - Seeking Alpha
Supernus Pharma's $795 Million Acquisition of Sage Therapeutics Boosts Shares - GuruFocus
Supernus’ $795 million bid sufficient for Sage - The Pharma Letter
Sage Therapeutics Stock Soars 36% After Sale to Supernus Pharmaceuticals. What We Know. - Barron's
Sage, following Setbacks, to sell to Supernus for $561M - BioPharma Dive
Supernus makes depression drug play with $795m Sage buyout - Yahoo Finance
Supernus enters depression drug market with up to $795 million Sage deal - Reuters
Finanzdaten der Supernus Pharmaceuticals Inc-Aktie (SUPN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.09%
0.96%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):